Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer Pharmaceutical Investing
Appeals Court Grants Trump Temporary Reprieve on Tariffs, "TACO" Taunts Gain Steam Resource Investing News
Pfizer's BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer Pharmaceutical Investing
Hearing Against Pfizer Set For 30 May In Contraceptive 'Depo-Provera' Multidistrict Litigation Overseen By Levin Papantonio Pharmaceutical Investing
